Sarepta releases 120 week eteplirsen data

Sarepta (SRPT) rallies 6% AH.

The company is out with data through week 120 in the Phase 2b eteplirsen extension study.

Summary: Patients in 30mg and 50mg cohorts able to perform the 6-minute walk test "experienced a decline of 13.9 meters, or less than 5%, from baseline in walking ability;" treatment benefit is a statistically significant 64.9 meters.

SRPT says it "now [has] more than two years of data with eteplirsen on the 6-minute walk test, the most accepted clinical outcome measure in DMD which demonstrates walking stability that [the company] believes would not be expected based on the natural history of this disease over the same time period." (PR)

From other sites
Comments (1)
  • jimgutner
    , contributor
    Comments (72) | Send Message
    I find this and the after hours stock activity extremely interesting. The FDA has already called into question - via comments by the SRPT CEO - the use of dystrophin as a marker and the walk test. I hope it works but the hope and naivity of biotech speculators never ceases to amaze me for their ignorance.
    15 Jan 2014, 07:52 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs